Anebulo Pharmaceuticals Analyst Ratings
Anebulo Pharmaceuticals Analyst Ratings
While ratings are subjective and will change, the latest Anebulo Pharmaceuticals (ANEB) rating was a maintained with a price target of $10.00 to $8.00. The current price Anebulo Pharmaceuticals (ANEB) is trading at is $3.06, which is out of the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 02/14/2023 | 161.33% | Benchmark | $10 → $8 | Maintains | Speculative Buy |
| 07/27/2022 | 96% | Ladenburg Thalmann | → $6 | Initiates Coverage On | → Buy |
| 05/25/2021 | 389.99% | Benchmark | → $15 | Initiates Coverage On | → Buy |
| 日期 | 上/下行 | 分析師公司 | 价格目標變更 | 評級變更 | 上一頁/目前評分 |
|---|---|---|---|---|---|
| 02/14/2023 | 161.33% | 基準 | 十美元 → 8 美元 | 維護 | 投機性購買 |
| 2022 年 7 月 27 日 | 96% | 拉登堡·塔爾曼 | → 6 美元 | 啟動覆蓋範圍 | → 購買 |
| 05/25/2021 | 389.99% | 基準 | → 15 美元 | 啟動覆蓋範圍 | → 購買 |
What is the target price for Anebulo Pharmaceuticals (ANEB)?
阿內布羅製藥（ANEB）的目標價格是多少？
The latest price target for Anebulo Pharmaceuticals (NASDAQ: ANEB) was reported by Benchmark on February 14, 2023. The analyst firm set a price target for $8.00 expecting ANEB to rise to within 12 months (a possible 161.33% upside). 2 analyst firms have reported ratings in the last year.
基準於 2023 年 2 月 14 日報導了阿內布羅製藥（納斯達克股票代碼：ANEB）的最新價格目標。該分析師公司設定了 8.00 美元的價格目標，預計 ANEB 將在 12 個月內上漲（可能上漲 161.33％）。2 家分析師公司在去年報告了評級。
What is the most recent analyst rating for Anebulo Pharmaceuticals (ANEB)?
安內布羅製藥（ANEB）的最新分析師評級是什麼？
The latest analyst rating for Anebulo Pharmaceuticals (NASDAQ: ANEB) was provided by Benchmark, and Anebulo Pharmaceuticals maintained their speculative buy rating.
Anebulo 製藥公司（納斯達克股票代碼：ANEB）的最新分析師評級由基準提供，而阿內布洛製藥保持其投機性買入評級。
When is the next analyst rating going to be posted or updated for Anebulo Pharmaceuticals (ANEB)?
安妮布羅製藥（ANEB）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Anebulo Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Anebulo Pharmaceuticals was filed on February 14, 2023 so you should expect the next rating to be made available sometime around February 14, 2024.
分析師在進行了廣泛的研究之後獲得了股票評級，其中包括通過公共財務報表，與 Anebulo Pharmacery 的高管和客戶交談以及收聽財報電話會議。大多數分析師每三個月這樣做一次，因此您應該每年每家公司獲得 4 個評級。對於阿內布羅製藥的最後評級提交 2 月 14, 2023 所以你應該期望下一個評級將在二月左右的某個時候提供 14, 2024.
Is the Analyst Rating Anebulo Pharmaceuticals (ANEB) correct?
分析師評級阿內布羅製藥（ANEB）是否正確？
While ratings are subjective and will change, the latest Anebulo Pharmaceuticals (ANEB) rating was a maintained with a price target of $10.00 to $8.00. The current price Anebulo Pharmaceuticals (ANEB) is trading at is $3.06, which is out of the analyst's predicted range.
儘管評級是主觀的並且會發生變化，但最新的安內布羅製藥（ANEB）評級維持，目標價格為 10.00 美元至 8.00 美元。目前的價格阿內布羅製藥（ANEB）的交易價格為 3.06 美元，超出了分析師的預測範圍。
譯文內容由第三人軟體翻譯。
